22 citations,
January 2019 in “British Journal of Clinical Pharmacology” HPV vaccines are generally safe but need further investigation for rare side effects.
17 citations,
September 2021 in “Dermatologic surgery” Microneedling is generally safe but can cause minor, temporary side effects and requires caution for some patients.
8 citations,
February 2017 in “Clinical Drug Investigation” Finasteride can cause sexual dysfunction and depression, which may persist and require hormonal treatment.
20 citations,
August 2019 in “Journal of Cosmetic Dermatology” Mesotherapy is generally safe but can cause adverse reactions due to its varied use and lack of standardization; individualized treatment is needed for these complications.
1 citations,
September 2020 The conclusion is that hair supplement ingredients may be unsafe and should be disclosed and proven safe before use.
8 citations,
February 2022 in “PubMed” The systematic review titled "Efficacy and safety profile of oral spironolactone use for androgenic alopecia" evaluates the effectiveness and safety of oral spironolactone in treating androgenic alopecia. The review concludes that oral spironolactone is an effective treatment option for androgenic alopecia, showing significant improvement in hair growth. The safety profile is generally favorable, with most side effects being mild and manageable. The review supports the use of oral spironolactone as a viable treatment for patients suffering from androgenic alopecia.
1 citations,
February 2018 in “Journal of Nepal Medical Association” Hair transplant surgery by Follicular Unit Extraction is mostly safe and gives good results with few complications.
September 2024 in “Actas Dermo-Sifiliográficas” Follicular unit extraction is safe and effective without bupivacaine and nerve blocks when using lignocaine with adrenaline.
April 2023 in “International journal of science and research” PRP therapy with a derma roller is a safe and effective treatment for female hair loss.
PRP therapy with Derma roller effectively promotes hair re-growth and reduces hair fall in women with pattern hair loss.
13 citations,
January 2011 in “Seizure” Extended-release valproate effectively reduced seizures and improved quality of life in epilepsy patients over 6 months, with some side effects.
June 2017 in “Poster presentations” All four treatments for early rheumatoid arthritis had similar safety profiles.
37 citations,
January 2016 in “Drug design, development and therapy” Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.
54 citations,
October 2019 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
January 2024 in “Journal of Crohn's and colitis” Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
13 citations,
January 2017 in “Plastic and reconstructive surgery. Global open” Juvéderm Ultra Plus is safe and effective for treating severe nasolabial folds in Chinese subjects.
September 2018 in “Journal of The American Academy of Dermatology” Ozenoxacin 1% cream is an effective and safe treatment for impetigo in children and adults.
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
19 citations,
March 2018 in “Expert Opinion on Drug Safety” Most treatments for spondyloarthritis are safe, but monitoring and careful selection based on patient risks are important.
May 2014 in “Journal of The American Academy of Dermatology” Tavaborole is a safe and effective toenail fungus treatment, with the 5% solution being the best option.
80 citations,
April 2017 in “Frontiers in Pharmacology” PDRN helps repair tissue and improve wound healing with a high safety profile.
23 citations,
October 2018 in “Expert Opinion on Drug Safety” Consider benefits and risks of new alopecia treatments for safety.
20 citations,
February 2017 in “Neurodegenerative disease management” Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
7 citations,
September 2013 in “Current Dermatology Reports” Some skin medications are safe for pregnant women, but others pose risks or should not be used.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
Minoxidil may help with hair regrowth and disease stabilization in scarring alopecia, but side effects vary, needing more research for consistent safety and effectiveness.
72 citations,
January 2016 in “Multiple Sclerosis and Related Disorders” Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.
12 citations,
June 2023 in “JAMA network open” JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.